HIV resident survival guide: Difference between revisions

Jump to navigation Jump to search
Line 55: Line 55:
Patient with high suspicion of having HIV in a highly prevalent region should have following diagnostic approach.<ref name="pmid30941943">{{cite journal| author=Korean Society for AIDS| title=The 2018 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans. | journal=Infect Chemother | year= 2019 | volume= 51 | issue= 1 | pages= 77-88 | pmid=30941943 | doi=10.3947/ic.2019.51.1.77 | pmc=6446007 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30941943  }} </ref>
Patient with high suspicion of having HIV in a highly prevalent region should have following diagnostic approach.<ref name="pmid30941943">{{cite journal| author=Korean Society for AIDS| title=The 2018 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans. | journal=Infect Chemother | year= 2019 | volume= 51 | issue= 1 | pages= 77-88 | pmid=30941943 | doi=10.3947/ic.2019.51.1.77 | pmc=6446007 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30941943  }} </ref>
<ref name="urlDIAGNOSTICS FOR HIV DIAGNOSIS - Consolidated Guidelines on HIV Testing Services - NCBI Bookshelf">{{cite web |url=https://www.ncbi.nlm.nih.gov/books/NBK316024/ |title=DIAGNOSTICS FOR HIV DIAGNOSIS - Consolidated Guidelines on HIV Testing Services - NCBI Bookshelf |format= |work= |accessdate=}}</ref>
<ref name="urlDIAGNOSTICS FOR HIV DIAGNOSIS - Consolidated Guidelines on HIV Testing Services - NCBI Bookshelf">{{cite web |url=https://www.ncbi.nlm.nih.gov/books/NBK316024/ |title=DIAGNOSTICS FOR HIV DIAGNOSIS - Consolidated Guidelines on HIV Testing Services - NCBI Bookshelf |format= |work= |accessdate=}}</ref>
<span style="font-size:85%">'''Abbreviations:''' '''RDTs:''' [[Rapid diagnostic test]]; '''EIAs:''' [[]]; '''CLIAs:''' [[chemiluminescence immunoanalysers]];'''ELAs:''' [[electrochemiluminescence immunoanalysers]];'''HIV:''' [[Human immunodeficiency virus]]</span>{{familytree/start}}
<span style="font-size:85%">'''Abbreviations:''' '''RDTs:''' [[Rapid diagnostic tests]]; '''EIAs:''' [[enzyme immunoassays]]; '''CLIAs:''' [[chemiluminescence immunoanalysers]];'''ELAs:''' [[electrochemiluminescence immunoanalysers]];'''HIV:''' [[Human immunodeficiency virus]]</span>{{familytree/start}}
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | | | | | | | | | | | | | A10 | | | | | A10= <div style="float: left; text-align: left; width: 15em; padding:1em;">'''Initial approach''' <br>  
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | | | | | | | | | | | | | A10 | | | | | A10= <div style="float: left; text-align: left; width: 15em; padding:1em;">'''Initial approach''' <br>  
❑ [[Inquire about symptoms|<span style="color:white;">inquire about symptoms</span>]]  
❑ [[Inquire about symptoms|<span style="color:white;">inquire about symptoms</span>]]  

Revision as of 21:19, 25 September 2020

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:


Overview

Human Immunodeficiency Virus, the agent causing Acquired Immunodeficiency Syndrome, is one of the leading infectious burden globally and fifth leading cause of disability in people of all ages. Belonging to the family of Retroviridae, it particularly infects the immune system cells such as CD4+ T cells, dendritic cells and macrophages. It has 2 serotypes with HIV-1 being most virulent and pathogenic. It is transmitted via sexual fluids(vaginal and semen), blood by percutaneous inoculation, Placenta(vertical transmission from mother to fetus) and breast milk. Due to competency of Antiretroviral therapy, it is now considered as chronic illness seen most commonly in mono-sexual men. Initially the symptoms are non specific until it develops into the last stage AIDS where patient present with opportunistic infections due to suppressed immunity. It is diagnosed by PCR, ELISA, western blot and Rapid antigen testing. ART and vaccines have shown promising results in treatment and prevention respectively. As prevention is the foundation, CDC recommends screening mono-sexual men, pregnant women, drug abusers ad sexually active heterosexuals. Despite better treatment, it remains a serious disease that require more efforts by health care providers in terms of surveillance and education.

Classification

WHO and CDC classify the HIV infected individuals on the basis of CD count:[1]

  • STAGE A- Asymptomatic (CD count > 500/μl)
  • STAGE B- Mild symptoms to symptoms of AIDS related complex (CD count between 400/μl and 200/μl)
  • STAGE C- AIDS defining illness (CD count <200/μl)

DISEASE PRESENTATION IN WEEKS[1]

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

DISEASE PRESENTATION IN MONTHS AND YEARS

Patients develop opportunistic infections and neoplasms when CD count becomes <200/μl.[1]

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Diagnosis

Patient with high suspicion of having HIV in a highly prevalent region should have following diagnostic approach.[2] [3]

Abbreviations: RDTs: Rapid diagnostic tests; EIAs: enzyme immunoassays; CLIAs: chemiluminescence immunoanalysers;ELAs: electrochemiluminescence immunoanalysers;HIV: Human immunodeficiency virus

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IF REACTIVE
 
 
IF NON REACTIVE
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Confirm with second line assay from any other serological fourth generation assays
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Report HIV negative
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
if positive
 
 
if negative
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Report HIV positive and retest prior to starting ART
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Repeat both first line and second line assay testing
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
if same results
 
 
if both negative
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Report HIV negative OR retest if high risk features present
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Perform third line assay
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
If positive-ask patient to return for testing in 14 days
 
 
if negative-report HIV negative
 

Treatment

Do's

  • The content in this section is in bullet points.

Don'ts

  • The content in this section is in bullet points.

References

  1. 1.0 1.1 1.2 German Advisory Committee Blood (Arbeitskreis Blut), Subgroup ‘Assessment of Pathogens Transmissible by Blood’ (2016). "Human Immunodeficiency Virus (HIV)". Transfus Med Hemother. 43 (3): 203–22. doi:10.1159/000445852. PMC 4924471. PMID 27403093.
  2. Korean Society for AIDS (2019). "The 2018 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans". Infect Chemother. 51 (1): 77–88. doi:10.3947/ic.2019.51.1.77. PMC 6446007. PMID 30941943.
  3. "DIAGNOSTICS FOR HIV DIAGNOSIS - Consolidated Guidelines on HIV Testing Services - NCBI Bookshelf".


Template:WikiDoc Sources